Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A5962

Richard E. Harris, Amanda M. Termuhlen, Lynette M. Smith, James Lynch, Michael M. Henry, Sherrie L. Perkins, Thomas G. Gross, Phyllis Warkentin, Adrianna Vlachos, Lauren Harrison, Mitchell S. Cairo

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


This prospective study was designed to determine the safety and efficacy of cyclophosphamide, BCNU, and etoposide (CBV) conditioning and autologous peripheral blood stem cell transplant (PBSCT) in children with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (HL and NHL). Patients achieving complete remission (CR) or partial remission (PR) after 2 to 4 courses of reinduction underwent a granulocyte-colony stimulating factor (G-CSF) mobilized PBSC apheresis with a target collection dose of 5 × 106 CD34+/kg. Those eligible to proceed received autologous PBSCT after CBV (7200 mg/m2, 450-300 mg/m2, 2400 mg/m2). Forty-three of 69 patients (30/39 HL, 13/30 NHL) achieved a CR/PR after reinduction. Thirty-eight patients (28 HL, 10 NHL) underwent PBSCT. All initial 6 patients who received BCNU at 450 mg/m2 experienced grade III or IV pulmonary toxicity compared to none of the subsequent 32 receiving 300 mg/m2 (P<.0001). The probability of overall survival (OS) at 3 years for all patients is 51% and for transplanted patients is 64%. The 3-year event-free survival (EFS) is 38% (45% for HL; 30% NHL). The 3-year EFS in transplanted patients is 66% (65% HL; 70% NHL). Initial duration of remission of ≥12 versus <12 months was associated with a significant increase in OS (3 years OS 70% versus 34%) (P=.003). BCNU at 300 mg/m2 in a CBV regimen prior to PBSCT is well tolerated in relapsed or refractory pediatric lymphoma patients. A short duration (<12 months) of initial remission is associated with a poorer prognosis. Last, a high percentage of patients achieving a CR/PR after reinduction therapy can be salvaged with CBV and autologlous PBSCT.

Original languageEnglish (US)
Pages (from-to)249-258
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Issue number2
StatePublished - Feb 2011
Externally publishedYes

Bibliographical note

Funding Information:
Financial disclosure: This was supported by Chair’s Grant, U10 CA98543 , Statistics and Data Center Grant , U10 CA98413 from the Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Department of Health and Human Services (COG) , as well as from CureSearch National Childhood Cancer Foundation . A complete listing of grant support for research conducted by CCG and POG before initiation of the COG grant in 2003 is available online at: .


  • Autologous transplant
  • CBV
  • HL
  • Lymphoma
  • NHL


Dive into the research topics of 'Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A5962'. Together they form a unique fingerprint.

Cite this